|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/31/23 Boston Scientific Corp. 8-K:5 1/29/23 11:235K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 33K 6: R1 Cover HTML 50K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- tm234966d1_8k_htm XML 21K 8: EXCEL IDEA Workbook of Financial Reports XLSX 8K 3: EX-101.DEF XBRL Definitions -- bsx-20230129_def XML 74K 4: EX-101.LAB XBRL Labels -- bsx-20230129_lab XML 104K 5: EX-101.PRE XBRL Presentations -- bsx-20230129_pre XML 71K 2: EX-101.SCH XBRL Schema -- bsx-20230129 XSD 14K 10: JSON XBRL Instance as JSON Data -- MetaLinks 27± 36K 11: ZIP XBRL Zipped Folder -- 0001104659-23-008661-xbrl Zip 20K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 31, 2023 ( i January 29, 2023)
i BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)
| i Delaware | i 1-11083 | i 04-2695240 | ||
| (State or other jurisdiction of incorporation) |
(Commission file number) |
(IRS employer identification no.) |
| i 300 Boston Scientific Way, i Marlborough, i Massachusetts | i 01752-1234 | |
| (Address of principal executive offices) | (Zip code) |
Registrant's telephone number, including area code: ( i 508) i 683-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
C:
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On January 29, 2023, Donna A. James informed the Company that she will not stand for re-election at the Company’s 2023 Annual Meeting. Ms. James has served as a member of the Board of Directors (Board) since July 2015 and currently serves as the chair of the Executive Compensation and Human Resources Committee and a member of the Nominating and Governance Committee. Ms. James will continue to serve as a director and in her committee roles until the 2023 Annual Meeting, to be held on May 4, 2023. Ms. James’ decision not to stand for re-election at the 2023 Annual Meeting is not the result of any disagreement with the Company.
Following the 2023 Annual Meeting, subject to their reelection by the stockholders, the Board will be composed of nine directors. The Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board following Ms. James’ departure is in the best interest of the Company.
C:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| January 31, 2023 | BOSTON SCIENTIFIC CORPORATION | |
| By: | /s/ Susan Thompson | |
| Susan Thompson | ||
| Vice President, Chief Corporate Counsel and Assistant Secretary |
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 5/4/23 | None on these Dates | |||
| Filed on: | 1/31/23 | |||
| For Period end: | 1/29/23 | |||
| List all Filings | ||||